SUPPLEMENTARY DATA

Table 1 of the supplementary data. Antithrombotic therapy at discharge

Variables	Total (n = 1225)	Suboptimal implant + nonintensive AT (n = 160)	Suboptimal implant + intensive AT (n = 308)	Optimal implant + nonintensive AT (n = 272)	Optimal implant + intensive AT (n = 485)
None	113 (9)	37 (23)	-	76 (28)	-
Aspirin	319 (26)	123 (77)	-	196 (72)	-
Aspirin + inhibitor P2Y$_{12}$	525 (43)	-	197 (64)	-	328 (68)
Warfarin	25 (2)	-	11 (4)	-	17 (3)
DOAC	122 (14)	-	66 (21)	-	101 (21)
LMWH	73 (6)	-	34 (11)	-	39 (8)

AT, antithrombotic therapy; DOAC, direct oral anticoagulation; LMWH, low molecular weight heparin.

Values are expressed as No. (%).

Table 2 of the supplementary data. Baseline demographic and clinical characteristics according to optimal implantation

Variables	Total (n = 1225)	Suboptimal implant (n = 468)	Optimal implant (n = 757)	*P*
Age, y	75.9 ± 10	75.7 ± 11.3	76.0 ± 10.0	.70
Female sex	429 (35.0)	168 (35.9)	261 (34.5)	.61
Body mass index, kg/m^2	27.4 ± 5.1	27.6 ± 5.3	27.2 ± 4.9	.23
AF type				.01
Paroxysmal	507 (41)	168 (36)	338 (45)	
Persistent	88 (7)	37 (8)	51 (7)	
Permanent	630 (52)	263 (56)	367 (48)	
Hypertension	1053 (86.0)	397 (84.8)	656 (86.7)	.47
Diabetes	377 (30.7)	144 (30.8)	232 (30.6)	.44
Smoking	167 (13.6)	61 (13.0)	106 (14.0)	.62
Chronic heart failure	318 (26.0)	132 (28.2)	186 (24.6)	.17
Previous CAD	404 (33.0)	158 (33.8)	246 (32.5)	.63
Previous ischemic stroke	255 (20.9)	87 (18.6)	168 (22.2)	.13
Previous bleed event	1052 (85.9)	405 (86.5)	647 (85.5)	.60
Type of bleed event				.87
Gastrointestinal	486 (46)	183 (45)	303 (47)	
Intracranial	338 (32)	134 (33)	204 (32)	
Abdominal/renal	76 (7)	26 (7)	50 (7)	
ENT bleed	51 (5)	22 (5)	29 (4)	
Pulmonary	19 (2)	7 (2)	13 (2)	
Others	85 (8)	34 (8)	51 (8)	
CHA$_2$DS$_2$-VASc score	4.4 ± 1.5	4.5 ± 1.4	4.4 ± 1.4	.50
Baseline stroke risk	6.0 ± 2.8	6.0 ± 2.9	5.9 ± 2.8	.73
HAS-BLED score	3.4 ± 1.0	3.4 ± 1.1	3.4 ± 1.0	.56
Previous AT therapy				
None	278 (22.7)	105 (22.4)	173 (22.9)	.87
Aspirin	366 (29.9)	131 (28.0)	235 (31.0)	.26
P2Y$_{12}$	91 (7.4)	36 (7.7)	55 (7.3)	.78
Warfarin	165 (13.5)	56 (12.0)	109 (14.4)	.22
DOAC	357 (29.1)	137 (29.3)	220 (29.1)	.94
LMWH	138 (11.3)	64 (13.7)	74 (9.8)	.07
eGFR, mL/min/1.73m^2	66.1 [46-98]	66.0 [46-97]	64.7 [46.8-93]	.87
Dialysis	65 (6.0)	18 (4.4)	47 (7.0)	.082
LVEF, %	55.4 ± 10.3	54.9 ± 11.1	55.7 ± 9.8	.21

AF, atrial fibrillation; ENT, ear, nose, throat; CAD, coronary artery disease, CHADS-VASc score, congestive heart failure, hypertension, age > 75 years, age 65 to 74 years, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, female sex; AT, antithrombotic therapy; eGFR, estimated glomerular filtrated rate; LVEF, left ventricular ejection fraction.

Values are expressed as No. (%), mean ± standard deviation, or median [interquartile range].

Table 3 of the supplementary data. Clinical outcomes at 3 months and 1 year of follow-up

Variables	Total (n = 1225)	Suboptimal implant + nonintensive AT (n = 160)	Suboptimal implant + intensive AT (n = 308)	Optimal implant + nonintensive AT (n = 272)	Optimal implant + intensive AT (n = 485)	*P*
Clinical outcomes at 3 months of follow-up						
Ischemic stroke (n = 1200)	4 (0.3)	0	4 (1.3)	0	0	.014
Systemic embolism	0	0	0	0	0	-
Major bleeding (BARC ≥3) (n = 1175)	46 (3.9)	6 (4.1)	12 (3.9)	12 (4.9)	16 (3.4)	.78
ICH (n = 1200)	1 (0.1)	0	1 (0.3)	0	0	1.00
All-cause mortality	19 (1.6)	2 (1.3)	6 (1.9)	4 (1.5)	7 (1.5)	.93
Clinical outcomes at 12 months of follow-up						
Ischemic stroke (n = 1200)	11 (0.9)	0	5 (1.6)	0	6 (1.2)	.11
Systemic embolism	2 (0.2)	0	1 (0.5)	1 (0.5)	0	.41
Major bleeding (BARC ≥3) (n = 1175)	82 (7.0)	10 (6.8)	25 (8.1)	19 (7.8)	28 (5.8)	.61
ICH (n = 1200)	1 (0.1)	0	1 (0.3)	0	0	1.00
All-cause mortality	110 (8.9)	14 (8.8)	29 (9.4)	22 (8.1)	45 (9.3)	.94

ICH, intracranial hemorrhage; DRT, device-related thrombus.

Values are expressed as No. (%).

Figure 1 of the supplementary data. Device-related thrombus rates according to implant features and antithrombotic therapy at discharge by device type. Proportion of patients with DRT by device type. A) Single-lobe group. B) Disc/lobe group. AT, antithrombotic therapy; DRT, device-related thrombus.